More than half of the pharmacies reported drug failures last year. The latest for the treatment of diabetes and those used for cases of hyperactivity and attention deficit were the ones that were missing the most.
The annual report on the management of infarmed medicines states that last year 1545 pharmacies notified drug absences. The situation happens when it is not possible to guarantee medical prescription over a period of less than 12 hours.
Dulagnitido and Semagluctido, better known by the trade names, Trulicity and Ozempic used to treat diabetes at the top of the list of 20 medicines with the most notified absences.
The high search for these drugs by people with obesity or those who want to only lose weight quickly has systematically caused a stop at stock.
Shortly after the list of the National Authority of Medicine and Health Products is methylphenidate, better known as Concerta or Rubifen. They are sought for the treatment of hyperactivity and attention deficit.
As for stock ruptures, only 14 medications had no alternatives available on the market. But still, Infarmed guarantees that he applied measures to patients not without treatment.
The authority of the drug is investigating the reasons for failures. The audit must be completed at the end of the month. He states that in more than half of cases of lack of medicines, pharmacies have not complied with the legal obligation to notify two months in advance of the shortage of stock.
Regarding the control of drug exports, Infarmed banned about nine thousand and five hundred requests last year and authorized more than 17,000.
At the top of the most exported drugs are creams for atopic eczema, contraceptive pills, skin inflammation ointments and drugs to treat type two diabetes in children and adults.
